dsRNA compositions and methods for treating HPV infection

US7956177B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• John Benson · Powell, US
• Birgit Bramlage · Ebikon, CH
• Kevin Fitzgerald · Brookline, US
• Pamela Tan · Kulmbach, DE
• Hans-Peter Vornlocher · Bayreuth, DE

Key dates

• Filing date: Mar 23, 2007
• Grant date: Jun 7, 2011
• Expiry date: Mar 23, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.